Colon Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology

Al B. Benson; Alan P. Venook; Mohamed Adam; George Chang; Yi Jen Chen; Kristen K. Ciombor; Stacey A. Cohen; Harry S. Cooper; Dustin Deming; Ignacio Garrido-Laguna; Jean L. Grem; Paul Haste; J. Randolph Hecht; Sarah Hoffe; Steven Hunt; Hisham Hussan; Kimberly L. Johung; Nora Joseph; Natalie Kirilcuk; Smitha Krishnamurthi; Midhun Malla; Jennifer K. Maratt; Wells A. Messersmith; Jeffrey Meyerhardt; Eric D. Miller; Mary F. Mulcahy; Steven Nurkin; Michael J. Overman; Aparna Parikh; Hitendra Patel; Katrina Pedersen; Leonard Saltz; Charles Schneider; David Shibata; Benjamin Shogan; John M. Skibber; Constantinos T. Sofocleous; Anna Tavakkoli; Christopher G. Willett; Christina Wu; Lisa A. Gurski; Jenna Snedeker; Frankie Jones

doi:10.6004/jnccn.2024.0029

Colon Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology

Al B. Benson, Alan P. Venook, Mohamed Adam, George Chang, Yi Jen Chen, Kristen K. Ciombor, Stacey A. Cohen, Harry S. Cooper, Dustin Deming, Ignacio Garrido-Laguna, Jean L. Grem, Paul Haste, J. Randolph Hecht, Sarah Hoffe, Steven Hunt, Hisham Hussan, Kimberly L. Johung, Nora Joseph, Natalie Kirilcuk, Smitha KrishnamurthiMidhun Malla, Jennifer K. Maratt, Wells A. Messersmith, Jeffrey Meyerhardt, Eric D. Miller, Mary F. Mulcahy, Steven Nurkin, Michael J. Overman, Aparna Parikh, Hitendra Patel, Katrina Pedersen, Leonard Saltz, Charles Schneider, David Shibata, Benjamin Shogan, John M. Skibber, Constantinos T. Sofocleous, Anna Tavakkoli, Christopher G. Willett, Christina Wu, Lisa A. Gurski, Jenna Snedeker, Frankie Jones

Research output: Contribution to journal › Article › peer-review

7 Scopus citations

Abstract

Colorectal cancer (CRC) is the fourth most frequently diagnosed cancer and the second leading cause of cancer death in the United States. Management of disseminated metastatic CRC involves various active drugs, either in combination or as single agents. The choice of therapy is based on consideration of the goals of therapy, the type and timing of prior therapy, the mutational profile of the tumor, and the differing toxicity profiles of the constituent drugs. This manuscript summarizes the data supporting the systemic therapy options recommended for metastatic CRC in the NCCN Guidelines for Colon Cancer.

Original language	English
Article number	e240029
Journal	Journal of the National Comprehensive Cancer Network : JNCCN
Volume	22
Issue number	2d
DOIs	https://doi.org/10.6004/jnccn.2024.0029
State	Published - Jun 2024

Keywords

Antineoplastic Combined Chemotherapy Protocols/therapeutic use
Colonic Neoplasms/diagnosis
Humans
Medical Oncology/standards
United States

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.6004/jnccn.2024.0029

Cite this

Benson, A. B., Venook, A. P., Adam, M., Chang, G., Chen, Y. J., Ciombor, K. K., Cohen, S. A., Cooper, H. S., Deming, D., Garrido-Laguna, I., Grem, J. L., Haste, P., Hecht, J. R., Hoffe, S., Hunt, S., Hussan, H., Johung, K. L., Joseph, N., Kirilcuk, N., ... Jones, F. (2024). Colon Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network : JNCCN, 22(2d), Article e240029. https://doi.org/10.6004/jnccn.2024.0029

@article{4a054527f465488b8de1344070adeeaf,

title = "Colon Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology",

abstract = "Colorectal cancer (CRC) is the fourth most frequently diagnosed cancer and the second leading cause of cancer death in the United States. Management of disseminated metastatic CRC involves various active drugs, either in combination or as single agents. The choice of therapy is based on consideration of the goals of therapy, the type and timing of prior therapy, the mutational profile of the tumor, and the differing toxicity profiles of the constituent drugs. This manuscript summarizes the data supporting the systemic therapy options recommended for metastatic CRC in the NCCN Guidelines for Colon Cancer.",

keywords = "Antineoplastic Combined Chemotherapy Protocols/therapeutic use, Colonic Neoplasms/diagnosis, Humans, Medical Oncology/standards, United States",

author = "Benson, {Al B.} and Venook, {Alan P.} and Mohamed Adam and George Chang and Chen, {Yi Jen} and Ciombor, {Kristen K.} and Cohen, {Stacey A.} and Cooper, {Harry S.} and Dustin Deming and Ignacio Garrido-Laguna and Grem, {Jean L.} and Paul Haste and Hecht, {J. Randolph} and Sarah Hoffe and Steven Hunt and Hisham Hussan and Johung, {Kimberly L.} and Nora Joseph and Natalie Kirilcuk and Smitha Krishnamurthi and Midhun Malla and Maratt, {Jennifer K.} and Messersmith, {Wells A.} and Jeffrey Meyerhardt and Miller, {Eric D.} and Mulcahy, {Mary F.} and Steven Nurkin and Overman, {Michael J.} and Aparna Parikh and Hitendra Patel and Katrina Pedersen and Leonard Saltz and Charles Schneider and David Shibata and Benjamin Shogan and Skibber, {John M.} and Sofocleous, {Constantinos T.} and Anna Tavakkoli and Willett, {Christopher G.} and Christina Wu and Gurski, {Lisa A.} and Jenna Snedeker and Frankie Jones",

note = "Publisher Copyright: {\textcopyright} JNCCN—Journal of the National Comprehensive Cancer Network.",

year = "2024",

month = jun,

doi = "10.6004/jnccn.2024.0029",

language = "English",

volume = "22",

journal = "Journal of the National Comprehensive Cancer Network : JNCCN",

issn = "1540-1405",

publisher = "Cold Spring Publishing LLC",

number = "2d",

}

Benson, AB, Venook, AP, Adam, M, Chang, G, Chen, YJ, Ciombor, KK, Cohen, SA, Cooper, HS, Deming, D, Garrido-Laguna, I, Grem, JL, Haste, P, Hecht, JR, Hoffe, S, Hunt, S, Hussan, H, Johung, KL, Joseph, N, Kirilcuk, N, Krishnamurthi, S, Malla, M, Maratt, JK, Messersmith, WA, Meyerhardt, J, Miller, ED, Mulcahy, MF, Nurkin, S, Overman, MJ, Parikh, A, Patel, H, Pedersen, K, Saltz, L, Schneider, C, Shibata, D, Shogan, B, Skibber, JM, Sofocleous, CT, Tavakkoli, A, Willett, CG, Wu, C, Gurski, LA, Snedeker, J & Jones, F 2024, 'Colon Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology', Journal of the National Comprehensive Cancer Network : JNCCN, vol. 22, no. 2d, e240029. https://doi.org/10.6004/jnccn.2024.0029

TY - JOUR

T1 - Colon Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology

AU - Benson, Al B.

AU - Venook, Alan P.

AU - Adam, Mohamed

AU - Chang, George

AU - Chen, Yi Jen

AU - Ciombor, Kristen K.

AU - Cohen, Stacey A.

AU - Cooper, Harry S.

AU - Deming, Dustin

AU - Garrido-Laguna, Ignacio

AU - Grem, Jean L.

AU - Haste, Paul

AU - Hecht, J. Randolph

AU - Hoffe, Sarah

AU - Hunt, Steven

AU - Hussan, Hisham

AU - Johung, Kimberly L.

AU - Joseph, Nora

AU - Kirilcuk, Natalie

AU - Krishnamurthi, Smitha

AU - Malla, Midhun

AU - Maratt, Jennifer K.

AU - Messersmith, Wells A.

AU - Meyerhardt, Jeffrey

AU - Miller, Eric D.

AU - Mulcahy, Mary F.

AU - Nurkin, Steven

AU - Overman, Michael J.

AU - Parikh, Aparna

AU - Patel, Hitendra

AU - Pedersen, Katrina

AU - Saltz, Leonard

AU - Schneider, Charles

AU - Shibata, David

AU - Shogan, Benjamin

AU - Skibber, John M.

AU - Sofocleous, Constantinos T.

AU - Tavakkoli, Anna

AU - Willett, Christopher G.

AU - Wu, Christina

AU - Gurski, Lisa A.

AU - Snedeker, Jenna

AU - Jones, Frankie

PY - 2024/6

Y1 - 2024/6

N2 - Colorectal cancer (CRC) is the fourth most frequently diagnosed cancer and the second leading cause of cancer death in the United States. Management of disseminated metastatic CRC involves various active drugs, either in combination or as single agents. The choice of therapy is based on consideration of the goals of therapy, the type and timing of prior therapy, the mutational profile of the tumor, and the differing toxicity profiles of the constituent drugs. This manuscript summarizes the data supporting the systemic therapy options recommended for metastatic CRC in the NCCN Guidelines for Colon Cancer.

AB - Colorectal cancer (CRC) is the fourth most frequently diagnosed cancer and the second leading cause of cancer death in the United States. Management of disseminated metastatic CRC involves various active drugs, either in combination or as single agents. The choice of therapy is based on consideration of the goals of therapy, the type and timing of prior therapy, the mutational profile of the tumor, and the differing toxicity profiles of the constituent drugs. This manuscript summarizes the data supporting the systemic therapy options recommended for metastatic CRC in the NCCN Guidelines for Colon Cancer.

KW - Antineoplastic Combined Chemotherapy Protocols/therapeutic use

KW - Colonic Neoplasms/diagnosis

KW - Humans

KW - Medical Oncology/standards

KW - United States

UR - http://www.scopus.com/inward/record.url?scp=85195888326&partnerID=8YFLogxK

U2 - 10.6004/jnccn.2024.0029

DO - 10.6004/jnccn.2024.0029

M3 - Article

C2 - 38862008

AN - SCOPUS:85195888326

SN - 1540-1405

VL - 22

JO - Journal of the National Comprehensive Cancer Network : JNCCN

JF - Journal of the National Comprehensive Cancer Network : JNCCN

IS - 2d

M1 - e240029

ER -

Colon Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this